Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Patent Reform Legislation Threatened By Biden Support For Vaccine IP Waiver, Republicans Say

Executive Summary

At hearing on Humira patent thicket, House Republicans express concern that Democrats’ support for transferring US intellectual property rights for COVID-19 vaccines to other countries is a bad sign for collaboration on legislation to reform patent abuses.

You may also be interested in...



USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing

Members of Congress, companies and government agencies want the Patent Office to change policies that they say impede generic drug competition. The latest effort is focused on PTO’s discretionary denial of inter partes review petitions, which is the subject of a bipartisan congressional letter and cert petition to the US Supreme Court.

From Pricing To Tax Havens: AbbVie On The Hot Seat Again With US Congress

Senate committee seeks details on company’s international tax practices as congress works to implement President Biden’s proposals on corporate tax reform.

Generic Industry’s Future May Include A Role In The Gene Therapy Space

Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel